Opinion

Video

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Author(s):

Richard Finn, MDDavid James Pinato, MD, MRCP, PhD

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Related Videos
Alexandra Drakaki, MD, PhD
Yuan Yuan, MD, PhD
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
Related Content
Ritu Salani, MD, director, Gynecologic Oncology, University of California Los Angeles
August 28th 2024

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Ritu Salani, MD, of UCLA Health
August 26th 2024

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

CIRT Plus Durvalumab/Tremelimumab in HCC| Image Credit: © stock.adobe.com
August 8th 2024

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

Chris Galloway, MD
August 1st 2024

EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC